Clin Osteol 2016; 21(1): 18-23

Osteoporóza a diabetes mellitus - klinické aspektyReview articles

M. ®urek, P. Horák

Keywords: diabetes mellitus, oste rózy v SUMMARY

Published: June 11, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
®urek M, Horák P. Osteoporóza a diabetes mellitus - klinické aspekty. Osteologický bulletin. 2016;21(1):18-23.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. NIH Consensus Development Panel on Osteoporosis Prevention D and T. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-795. Go to original source...
    2. Jackuliak P, Payer J. Osteoporosis, fractures, and diabetes. Int J Endocrinol 20 2014:1-10. Go to original source...
    3. Loder RT. The influence of diabetes mellitus on the healing of closed fractures. Clin Orthop Relat Res 1988;210-216. Go to original source...
    4. Forsén L, Meyer HE, Midthjell K, and Edna TH. Diabetes mellitus and the inci­ dence of hip fracture: results from the Nord-Tr0ndelag Health Survey. Diabetologia 1999;42:920-925. Go to original source...
    5. Janghorbani M, Feskanich D, Willett WC, Hu F. Prospective Study of Diabetes and Risk of Hip Fracture: The Nurses' Health Study. Diabetes Care 2006; 29:1573-1578. Go to original source...
    6. Bonds DE, Larson JC, Schwartz A V, Strotmeyer ES, Robbins J, Rodriguez BL et al. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab 2006;91:3404-3410. Go to original source...
    7. Vestergaard P. Discrepancies in bone mineral density and fracture risk in pati with type 1 and type 2 diabetes - a meta-analysis. Osteoporos Int 2007;18: 427 444. Go to original source...
    8. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007;166: 495-505. Go to original source...
    9. Yamamoto M, Yamaguchi T, Yamauchi M, Kaji H, Sugimoto T. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic com­ plications. J Bone Miner Res 2009;24:702-709. Go to original source...
    10. Rakel A, Sheehy O, Rahme E, Lelorier J. Does diabetes increase the risk for fr tures after solid organ transplantation? A nested case-control study. J Bone Miner Res 2007;22:1878-1884. Go to original source...
    11. Kemink SA, Hermus AR, Swinkels LM, Lutterman JA, Smals AG. Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology. J Endocrinol Invest Kemink, S. A. Division of Endocrinology, University Hospital Nijmegen, The Netherlands.; 2000;23:295-303. Go to original source...
    12. Dooms L, Bouillon R, Ravltssin E. Influence of Age, Sex, and Insulin on Osteoblast Function: Osteoblast Dysfunction in Diabetes Mellitus. J Clin Endocrinol Metab 1995;80:1194-1202. Go to original source...
    13. Weber G, Beccaria L, de'Angelis M, Mora S, Galli L, Cazzuffi M et al. Bone in young patients with type I diabetes. Bone Miner 1990;8:23-30. Go to original source...
    14. Compston JE, Smith EM, Matthews C, Schofield P. Whole body composition and regional bone mass in women with insulin-dependent diabetes mellitus. Clin Endocrinol (Oxf). 1994;41:289-293. Go to original source...
    15. Mastrandrea LD, Wactawski-Wende J, Donahue RP, Hovey KM, Clark A, Quattrin T. Young women with type 1 diabetes have lower bone mineral density that persists over time. Diabetes Care 2008;31:1729-1735. Go to original source...
    16. Ma L, Oei L, Jiang L, Estrada K, Chen H, Wang Z et al. Association between bo­ ne mineral density and type 2 diabetes mellitus: A meta-Analysis of observatio studies. Eur J Epidemiol 2012;27:319-332. Go to original source...
    17. Majima T, Komatsu Y, Yamada T, Koike Y, Shigemoto M, Takagi C, Hatanaka I, Nakao K. Decreased bone mineral density at the distal radius, but not at the lum­ bar spine or the femoral neck, in Japanese type 2 diabetic patients. Osteopo 2005;16:907-913. Go to original source...
    18. Shan PF, Wu XP, Zhang H, Cao XZ, Yuan LQ, Liao EY. Age-related bonemine­ ral density, osteoporosis rate and risk of vertebral fracture in mainland women with type 2 diabetes mellitus. J EndocrinolInvest 2011;34:190-196. Go to original source...
    19. Yamamoto M, Yamaguchi T, Yamauchi M, Kaji H, Sugimoto T. Bone mineral density is not sensitive enough to assess the risk of vertebral fractures in typ diabetic women. Calcif Tissue Int 2007;80:353-358. Go to original source...
    20. Hamann C, Kirschner S, Gunther K-P, Hofbauer LC. Bone, sweet bone-osteo­ porotic fractures in diabetes mellitus. Nat Rev Endocrinol Nature Publishing Group; 2012;8:297-305. Go to original source...
    21. Khalil N, Sutton-Tyrrell K, Strotmeyer ES, Greendale G a., Vuga M, Selzer F et al. Menopausal bone changes and incident fractures in diabetic women: A cohort study. Osteoporos Int 2011;22:1367-1376. Go to original source...
    22. Schwartz AV, Ewing SK, Porzig AM, McCulloch CE, Resnick HE, Hillier T et al. Diabetes and change in bone mineral density at the hip, calcaneus, spine, a dius in older women. Front Endocrinol (Lausanne) 2013;4:1-9. Go to original source...
    23. Hamilton EJ, Rakic V, Davis W, Paul Chubb S, Kamber N, Prince RL et al. A five-year prospective study ofbone mineral density in men and women with d betes: the Fremantle Diabetes Study. Acta Diabetol 2012;49:153-158. Go to original source...
    24. Vasilkova O, Mokhort T, Sanec I, Sharshakova T, Hayashida N, Takamura N. Testosterone is an independent determinant of bone mineral density in men type 2 diabetes mellitus. Clin Chem Lab Med 2011;49:99-103. Go to original source...
    25. Hadjidakis DI, Androulakis II, Mylonakis AM, Sfakianakis ME, Raptis E, Papaefstathiou G et al. Diabetes in postmenopause: different influence on bone mass accordi 117:199-204.
    26. Di Somma C, Rubino M, Faggiano A et al. type 2 diabetes. Endocrine 2013;43:651-658. Go to original source...
    27. Anaforoglu I, Nar-Demirer A, Bascil-Tutuncu N, Ertorer ME. Prevalenc oporosis and factors affecting bone mineral density among postmenopausal Turkish women with type 2 diabetes. J Diabetes Complic 2009;23:12-17. Go to original source...
    28. Strotmeyer ES, Cauley JA, Schwartz AV, et al. Diabetes is associated ind dently of body composition with BMD and bone volume in older white and black men and women: the Health, Aging, and Body Composition Study. J Bone Miner Res 2004;19:1084-1091. Go to original source...
    29. Schaffler MB, Burr DB. S ty. J Biomech 1988;21:13-16. Go to original source...
    30. SeemanE. Is a change in bone mineral density of anti-fracture efficacy? Bone 2007;41:308-317. Go to original source...
    31. Holzer G, von Skrbensky G, Holzer LA, Pichl W. Hip fractures and the contribu­ tion of cortical 2009;24:468-474.
    32. MacNeil JA, Boyd SK. Accuracy of high-resolution peripheral quan puted tomography for measurement of bone quality. Med Eng Phys 2007; 29:1096-1105. Go to original source...
    33. Patsch JM, Burghardt AJ, Yap SP et al. Increased cortical porosity in Typ betic postmenopausal women with fragility fractures. J Bone Miner Res;28: 313-324.
    34. Shanbhogue VV, Hansen S, Frost M, J0rgensen NR, Hermann AP, Henriksen JE, Brixen K. Compromised cortical bone compartment in type 2 diabetes mellitus patients with microvascular disease. Eur J Endocrinol 2015;174:115-124. Go to original source...
    35. Burghardt AJ, Issever AS, Schwartz AV et al. High-resolution peripheral quan tative computed tomographic imaging of cortical and trabecular bone microarchi­ tecture in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010; 95:5045-5055. Go to original source...
    36. Shanbhogue VV, Hansen S, J0rgensen NR, Brixen K, Gravholt CH. Bone Geometry, Volumetric Density, Microarchitecture, and Estimated Bone Strength Assessed by HR-pQCT in Klinefelter Syndrome. J Bone Miner Res 2014;29: 2474-2482. Go to original source...
    37. Leslie WD, Aubry-Rozier B, Lamy O, Hans D. TBS (trabecular bone score) and diabetes-related fracture risk. J Clin Endocrinol Metab 2013;98:602-609. Go to original source...
    38. Abdalrahaman N, McComb C, Foster JE, McLean J, Lindsay RS, McClure J et al. Deficits in Trabecular Bone Microarchitecture in Young Women With Type 1 Diabetes Mellitus. J Bone Miner Res 2015;30:1386-1393. Go to original source...
    39. Räkel A, Sheehy O, Rahme E, LeLorier J. Osteoporosis among patients with type 1 and type 2 diabetes. Diabetes Metab 2008;34:193-205. Go to original source...
    40. Oz SG, Guven GS, Kilicarslan A, Calik N, Beyazit Y, Sozen T. Evaluation of bo­ ne metabolism and bone m Assoc 2006;98:1598-1604.
    41. Dobnig H, Piswanger-Solkner JC, Roth M, Obermayer-Pietsch B, Tiran A, St A, Maier E, Maritschnegg P, Sieberer C, Fahrleitner-Pammer A Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and ture risk. J Clin Endocrinol Metab 2006;91:3355-3363. Go to original source...
    42. Krakauer JC, McKenna MJ, Buderer NF, Rao DS, Whitehouse FW, Parfitt AM. Bone loss and bone turnover in diabetes. Diabetes 1995;44:775-782. Go to original source...
    43. Gerdhem P, Isaksson A, Akesson K, Obrant KJ. Increased bone density and de­ creased bone turnover, but no evident alteration of fracture susce ly women with diabetes mellitus. Osteoporos Int 2005;16:1506-1512. Go to original source...
    44. Clemens TL, Karsenty G. The osteoblast: An insulin target cell controlling glu se homeostasis. J. Bone Miner Res 2011;26:677-680. Go to original source...
    45. Yamamoto M, Yamaguchi T, Nawata K, Yamauchi M, Sugimoto T. Decreased PTH levels accompanied by low bone formation are associated with vertebral frac­ tures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 2012;97:1277-1284. Go to original source...
    46. Verhaeghe J, Visser WJ, Einhorn TA, Bouillon R. Osteoporosis and diabetes: Lessons from the diabetic BB rat. Horm Res 1990; 34:245-248. Go to original source...
    47. Silva MJ, Brodt MD, Lynch MA, McKenzie JA, Tanouve KM, Nyman JS, Wang X. Type 1 diabetes in young rats leads to progressive trabecular bone loss, cessa­ tion of cortical bone growth, and diminished whole bone strength and fatigue life. J Bone Miner Res 2009; 24:1618-1627. Go to original source...
    48. Krakauer JC, McKenna MJ, Buderer NF, Rao DS, Whitehouse FW, Parfitt AM. Bone loss and bone turnover in diabetes. Diabetes 1995;44:775-782. Go to original source...
    49. Bouillon R. Diabetic bone disease. Calcif Tissue Int 1991 49:155-160. Go to original source...
    50. McNair P. Bone mineral metabolism in human type 1 (insulin dependent) diabe­ tes mellitus. Dan Med Bull 1988 35:109-121.
    51. Armas LAG, Akhter MP, Drincic A, Recker RR. Trabecular bone histomorphometry in humans with Type 1 Diabetes Mellitus. Bone 2012;50:91-96. Go to original source...
    52. Gennari L, Merlotti D, Valenti R, Ceccarelli E, Ruvio M, Pietrini MG, Capodarca C, Franci MB, Campagna MS, Calabro A, Cataldo D, Stolakis K, Dotta F, Nuti R. Circulating sclerostin levels and bone turnover in type 1 and type 2 dia­ betes. J Clin Endocrinol Metab 2012;97:1737-1744. Go to original source...
    53. Gaudio A, Privitera F, Battaglia K, Torrisi V, Sidoti MH, Pulvirenti I, et al. Sclerostin levels associated with inhibition of the Wnt/p-catenin signaling an duced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab 2012; 97:3744-3750. Go to original source...
    54. Ardawi MS, Akhbar DH, Alshaikh Aet al. Increased serum sclerostin and de sed serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes. Bone 2013;56:355-362. Go to original source...
    55. Gennari L, Merlotti D, Valenti R, Ceccarelli R, Ruvio M, Pietrini MG, et al. Circulating sclero 2012;97:1737-1744.
    56. Yamamoto M, Yamauchi M, Sugimoto T. Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus. J Clin Endocri Metab 2013;98:4030-4037. Go to original source...
    57. Morales-Santana S, Garcia-Fontana B, Garcia-Martin A, RozasMoreno P, GarciaSalced JA, Reyes-Garcia R, et al. Atheroscleroic disease in type 2 diabetes is as­ sociated with an increase in sclerostin levels. Diabetes Care 2013;36:1667-1674. Go to original source...
    58. Hamann C, Rauner M, Hohna Y et al. Sclerostin antibody treatment improves bo­ ne mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. J Bone Miner Res 2013;28:627-638. Go to original source...
    59. [homepage on the Internet]. Romosozumab. A service of the US National Institutes of Health. Available from: Search=Search. Accessed February 11, 2015. ClinicalTrials.gov ClinicalTrials.gov http://clinicaltrials.gov/ct2/results?term=romosozumab
    60. Inzerillo AM, Epstein S. Osteoporosis and diabetes mellitus. Rev Endocr Metab Disord 2004;53:261-268. Go to original source...
    61. Schwartz AV, VittinghoffE, Bauer DC et al. Association of BMD and FRAX sco­ re with risk of fracture in older adults with type 2 diabetes. JAMA 2011; 305: 2184-2192. Go to original source...
    62. Giangregorio LM, Leslie WD, Lix LM et al. FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res 2012;27:301-308. Go to original source...
    63. Leslie WD, Rubin MR, Schwartz AV, Kanis JA Type 2 diabetes and bone. J Bone Miner Res 2012;27:2231-2237. Go to original source...
    64. Inaba M, Terada M, Koyama H, et al. Influence of high glucose on 1,25-dihydroxyvitamin D3-induced effect on human osteoblast-like MG-63 cells. Journal of Bone and Mineral Research 1995;10:1050-1056. Go to original source...
    65. Inaba M, Nishizawa Y, Mita K et al. Poor glycemic control impairs the response of biochemical parameters of bone formation and resorption to exogenous 1,25-Dihydroxyvitamin D3 in Patients with Type 2 Diabetes. Osteoporosis International 1999;9:525-531. Go to original source...
    66. Danielson KK, Elliott ME, LeCaire T, Binkley, J^lta M. Poor glycemic control is associated with low BMD detected in premenopausal women with Type 1 Diabetes. Osteoporos International 2009;20:923-933. Go to original source...
    67. Rosato MT, Schneider SH, Shapses SA Bone turnover and insulinlike growth fac­ tor I levels increase after improved glycemic control in noninsulin-dependent dia­ betes mellitus. Calcified Tissue International 1998;63:107-111. Go to original source...
    68. Okazaki R, Totsuka Y, Hamano K, et al. Metabolic improvement of poorly con­ trolled noninsulin-dependent diabetes mellitus decreases bone turnover. Journal of Clinical Endocrinology and Metabolism 1997;82:2915-2920. Go to original source...
    69. Dawson-Hughes B, Mithal A, Bonjour JP et al. IOF position statement: vitamin D recommendations for older adults. Osteoporosis International 2010;21:1151-1154. Go to original source...
    70. Rizzoli R, Boonen S, Brandi ML et al. Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the EuropeanSociety for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Curr Med Res Opin. 2013;29:305-313. Go to original source...
    71. Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J et al. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postme­ nopausal osteoporotic women. J Clin Endocrinol Metab 2001;86:1116-1125. Go to original source...
    72. Keegan TH, Schwartz A V, Bauer DC, Sellmeyer DE, Kelsey JL. Effect of alen­ dronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial. Diabetes Care 2004;27: 1547-1553. Go to original source...
    73. Ikeda T. Long-Term Effect of Alendronate on Bone Mineral Density in Post­ menopausal Type 2 Diabetes Mellitus. J Diabetes Metab 2012;01:2-5. Go to original source...
    74. Dagdelen S, Sener D, Bayraktar M. Influence of type 2 diabetes mellitus on b mineral density response to bisphosphonates in late postmenopausal osteoporosis. Adv Ther 2007;24:1314-1320. Go to original source...
    75. Hamann C, Rauner M, Hohna Y, Bernhardt R, Mettelsiefen J, Goettsch C, Gunther KP, Stolina M, Han CY,Asuncion FJ, Ominsky MS, Hofbauer LC. Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. J Bone Miner Res 2013;28: 627-638. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.